A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect

mAbs

Volumn 8, Issue 3, 2016, Pages 468-477

  Wang, Wei ^a   Sun, Lina ^b   Li, Tiansheng ^a   Ma, Yanchun ^c   Li, Jisu ^d   Liu, Yang ^b   Li, Meng ^a   Wang, Lei ^a   Li, Chuan ^b   Xie, Youhua ^a   Wen, Yumei ^a   Liang, Mifang ^b   Chen, Li ^a   Tong, Shuping ^a  

^a FUDAN UNIVERSITY   (China)

^b Key Laboratory for Medical Virology NHFPC National Institute for Viral Disease Control and Prevention China CDC   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d BROWN UNIVERSITY   (United States)

Author keywords

Anti S; hepatitis B immune globulin; hepatitis B virus; human monoclonal antibody; neutralization; small envelope protein; transgenic mice

Indexed keywords

ENVELOPE PROTEIN; HEPATITIS B SURFACE ANTIGEN; MONOCLONAL ANTI S ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VITRONECTIN; HEPATITIS B ANTIBODY; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; MOUSE; NONHUMAN; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; PROTEIN CONFORMATION; VIRUS NEUTRALIZATION; ANIMAL; CHO CELL LINE; CRICETULUS; DISEASE MODEL; FEMALE; HAMSTER; IMMUNOLOGY; MALE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MICE;

EID: 84961205301     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1134409     Document Type: Article

References (37)

1. W.H.Gerlich. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immun 2015; 204:39-55; http://dx.doi.org/10.1007/s00430-014-0373-y
2. X.Liang, S.Bi, W.Yang, L.Wang, G.Cui, F.Cui, Y.Zhang, J.Liu, X.Gong, Y.Chen, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis 2009; 200:39-47; PMID:19469708; http://dx.doi.org/10.1086/599332
3. D.Ganem, A.M.Prince. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med 2004; 350:1118-29; PMID:15014185; http://dx.doi.org/10.1056/NEJMra031087
4. A.Schulze, P.Gripon, S.Urban. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007; 46:1759-68; PMID:18046710; http://dx.doi.org/10.1002/hep.21896
5. C.M.Leistner, S.Gruen-Bernhard, D.Glebe. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008; 10:122-33; PMID:18086046; http://dx.doi.org/10.1111/j.1462-5822.2007.01023.x
6. C.Sureau, J.Salisse. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013; 57:985-94; PMID:23161433; http://dx.doi.org/10.1002/hep.26125
7. H.Yan, G.Zhong, G.Xu, W.He, Z.Jing, Z.Gao, Y.Huang, Y.Qi, B.Peng, H.Wang, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e49; http://dx.doi.org/10.7554/eLife.00049
8. Y.Ni, F.A.Lempp, S.Mehrle, S.Nkongolo, C.Kaufman, M.Falth, J.Stindt, C.Koniger, M.Nassal, R.Kubitz, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146:1070-83; PMID:24361467; http://dx.doi.org/10.1053/j.gastro.2013.12.024
9. A.R.Neurath, B.Seto, N.Strick. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 1989; 7:234-6; PMID:2476893; http://dx.doi.org/10.1016/0264-410X(89)90235-1
10. R.Eren, E.Ilan, O.Nussbaum, I.Lubin, D.Terkieltaub, Y.Arazi, O.Ben-Moshe, A.Kitchinzky, S.Berr, J.Gopher, et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 2000; 32:588-96; PMID:10960454; http://dx.doi.org/10.1053/jhep.2000.9632
11. D.Glebe, M.Aliakbari, P.Krass, E.V.Knoop, K.P.Valerius, W.H.Gerlich. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003; 77:9511-21; PMID:12915565; http://dx.doi.org/10.1128/JVI.77.17.9511-9521.2003
12. F.E.Andre, A.J.Zuckerman. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994; 44:144-51; PMID:7852954; http://dx.doi.org/10.1002/jmv.1890440206
13. N.Ogata, L.Ostberg, P.H.Ehrlich, D.C.Wong, R.H.Miller, R.H.Purcell. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A 1993; 90:3014-8; PMID:8464917; http://dx.doi.org/10.1073/pnas.90.7.3014
14. R.Heijtink, W.Paulij, P.van Bergen, M.van Roosmalen, D.Rohm, B.Eichentopf, E.Muchmore, R.de Man, A.Osterhaus. In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J Gen Virol 1999; 80 (Pt 6):1529-35; PMID:10374972; http://dx.doi.org/10.1099/0022-1317-80-6-1529
15. E.Walter, R.Keist, B.Niederost, I.Pult, H.E.Blum. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996; 24:1-5; PMID:8707245; http://dx.doi.org/10.1002/hep.510240101
16. M.Dandri, M.R.Burda, E.Torok, J.M.Pollok, A.Iwanska, G.Sommer, X.Rogiers, C.E.Rogler, S.Gupta, H.Will, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33:981-8; PMID:11283864; http://dx.doi.org/10.1053/jhep.2001.23314
17. F.V.Chisari, C.A.Pinkert, D.R.Milich, P.Filippi, A.McLachlan, R.D.Palmiter, R.L.Brinster. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985; 230:1157-60; PMID:3865369; http://dx.doi.org/10.1126/science.3865369
18. P.Gripon, S.Rumin, S.Urban, J.Le Seyec, D.Glaise, I.Cannie, C.Guyomard, J.Lucas, C.Trepo, C.Guguen-Guillouzo. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99:15655-60; PMID:12432097; http://dx.doi.org/10.1073/pnas.232137699
19. C.J.Chu, A.S.Lok. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35:1274-6; PMID:11981779; http://dx.doi.org/10.1053/jhep.2002.33161
20. H.Norder, A.M.Courouce, P.Coursaget, J.M.Echevarria, S.D.Lee, I.K.Mushahwar, B.H.Robertson, S.Locarnini, L.O.Magnius. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289-309; PMID:15564741; http://dx.doi.org/10.1159/000080872
21. H.Guo, D.Jiang, T.Zhou, A.Cuconati, T.M.Block, J.T.Guo. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol 2007; 81:12472-84; PMID:17804499; http://dx.doi.org/10.1128/JVI.01123-07
22. J.Ren, L.Wang, Z.Chen, Z.M.Ma, H.G.Zhu, D.L.Yang, X.Y.Li, B.I.Wang, J.Fei, Z.G.Wang, et al. Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy. J Med Virol 2006; 78:551-60; PMID:16555286; http://dx.doi.org/10.1002/jmv.20575
23. C.Zhao, C.Y.Fang, X.C.Tian, L.Wang, P.Y.Yang, Y.M.Wen. Proteomic analysis of hepatitis B surface antigen positive transgenic mouse liver and decrease of cyclophilin A. J Med Virol 2007; 79:1478-84; PMID:17705187; http://dx.doi.org/10.1002/jmv.20945
24. D.S.Dimitrov, J.D.Marks. Therapeutic antibodies: current state and future trends–is a paradigm change coming soon? Methods Mol Biol 2009; 525:1-27; PMID:19252861; http://dx.doi.org/10.1007/978-1-59745-554-1_1
25. A.Casadevall, E.Dadachova, L.A.Pirofski. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695-703; PMID:15372080; http://dx.doi.org/10.1038/nrmicro974
26. W.A.Marasco, J.Sui. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25:1421-34; PMID:18066039; http://dx.doi.org/10.1038/nbt1363
27. D.Schrama, R.A.Reisfeld, J.C.Becker. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-59; PMID:16424916; http://dx.doi.org/10.1038/nrd1957
28. C.J.Ryu, P.Gripon, H.R.Park, S.S.Park, Y.K.Kim, C.Guguen-Guillouzo, O.J.Yoo, H.J.Hong. In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen. J Med Virol 1997; 52:226-33; PMID:9179773; http://dx.doi.org/10.1002/(SICI)1096-9071(199706)52:2%3c226::AID-JMV18%3e3.0.CO;2-I
29. F.Nimmerjahn, J.V.Ravetch. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10.1038/nri2206
30. L.T.Vogelpoel, D.L.Baeten, E.C.De Jong, J.Den Dunnen. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol 2015; 6:79; PMID:25759693; http://dx.doi.org/10.3389/fimmu.2015.00079
31. W.R.Strohl. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20:685-91; PMID:19896358; http://dx.doi.org/10.1016/j.copbio.2009.10.011
32. P.J.Carter. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57; PMID:16622479; http://dx.doi.org/10.1038/nri1837
33. A.K.Kashyap, J.Steel, A.F.Oner, M.A.Dillon, R.E.Swale, K.M.Wall, K.J.Perry, A.Faynboym, M.Ilhan, M.Horowitz, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 2008; 105:5986-91; PMID:18413603; http://dx.doi.org/10.1073/pnas.0801367105
34. L.Sun, X.Lu, C.Li, M.Wang, Q.Liu, Z.Li, X.Hu, J.Li, F.Liu, Q.Li, et al. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 2009; 4:e5476; PMID:19421326; http://dx.doi.org/10.1371/journal.pone.0005476
35. C.R.Barbas, A.S.Kang, R.A.Lerner, S.J.Benkovic. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 1991; 88:7978-82; PMID:1896445; http://dx.doi.org/10.1073/pnas.88.18.7978
36. C.R.Barbas, D.R.Burton. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol 1996; 14:230-4; PMID:8771795; http://dx.doi.org/10.1016/0167-7799(96)10029-9
37. M.Liang, S.Dubel, D.Li, I.Queitsch, W.Li, E.K.Bautz. Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J Immunol Methods 2001; 247:119-30; PMID:11150543; http://dx.doi.org/10.1016/S0022-1759(00)00322-7